"Mount Sinai, Sema4 Data Scientists Tout Brain Cancer Breakthrough" - Bernie Monegain

Scientists at the Icahn School of Medicine at Mount Sinai and Sema4, a company of scientists, doctors, engineers, and genetic counselors, with roots at Mount Sinai, have pinpointed a biomarker for brain cancer. The glioblastoma study validated a biomarker indicative of a patient's prognosis and likely response to specific therapies. The results of the research were published in an article in the October 15 issue of Cancer Research. "It was truly remarkable to see our predictive model yield a new set of molecular subtypes, which appear to be far more indicative of prognosis and therapeutic response than existing subtypes,” said Jun Zhu, PhD, professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai and head of data sciences at Sema4. "These findings underscore the significant potential we see to improve patient outcomes by investing in predictive modeling of even the most complex types of cancer,” said Eric Schadt, PhD, dean of precision medicine, professor of genetics and genomic sciences at the Icahn School of Medicine at Mount Sinai and Sema4 CEO.

- Eric Schadt, PhD, Dean, Precision Medicine, Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai

- Jun Zhu, PhD, Professor, Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai

- Raymund L. Yong, MD, Assistant Professor, Neurosurgery, Oncological Sciences, Icahn School of Medicine at Mount Sinai

Learn more

Additional coverage:

Technology Networks